Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / HUMA - Humacyte to Host In-Person KOL Event at the New York EDITION on September 20 2023 | Benzinga


HUMA - Humacyte to Host In-Person KOL Event at the New York EDITION on September 20 2023 | Benzinga

  • DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced it will host an in-person KOL event on Wednesday, September 20, 2023 at 3:00pm ET at The New York EDITION Hotel.

    The event will feature Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and his patient Devin Barnett, who will discuss the recently announced top line clinical data from the Humacyte Phase 2/3 V005 vascular trauma trial, the unmet clinical need in treating these injuries, and the use of the Human Acellular Vessel™ (HAV™) in repairing blood vessels.

    The HAV is an off-the-shelf, universally implantable bioengineered human tissue, that is being studied in traumatic vascular injury and other vascular diseases. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

    Event Details

    Title:
    KOL and Patient Perspectives: Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
    Location:
    The New York EDITION (Flatiron District)
    Date:
    Wednesday, September 20, 2023
    Time:
    3:00 PM ET
    RSVP:
    Click Here
    Webcast/Replay:
    Click Here

    About Michael Curi, MD, MPA
    Dr. Curi is a proud graduate of New Jersey Medical School and received his undergraduate degree from Lafayette College. Prior to medical school he obtained a Master's Degree in Public Administration studying Health Policy & Management from New York University. He completed his surgical residency at University of Chicago where he spent an additional 2 years performing cutting-edge research into the treatment of vascular disease utilizing gene therapy and novel biological agents. He then completed an advanced fellowship in Vascular & Endovascular Surgery at Washington University in St. Louis, where ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Humacyte Inc.
    Stock Symbol: HUMA
    Market: NASDAQ
    Website: humacyte.com

    Menu

    HUMA HUMA Quote HUMA Short HUMA News HUMA Articles HUMA Message Board
    Get HUMA Alerts

    News, Short Squeeze, Breakout and More Instantly...